ArticleInternational journal of clinical and experimental pathology2018
Combined effects of fibroblast growth factor 2 and dexamethasone on differentiation of human cementoblasts.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Roles of Wnt signaling pathway in cementum formation, cementum regeneration, and cementocyte function.Journal of Zhejiang University. Science. B · 2026Review
- The role of cementoblasts in root resorption induced by orthodontic treatment: from mechanosensation to repair potential.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblast growth factor 2 (FGF-2) is known to play a pivotal role in bone remodeling and osteogenesis. Dexamethasone is a potent modulator of osteogenic differentiation and can increase the bone formation capacity of cementoblasts. However, the combined effects of FGF-2 and dexamethasone on cementoblasts and the way they regulate the activities of cementoblasts have not been fully understood. The aim of this study was to clarify and investigate the effects of the combination of FGF-2 and dexamethasone on growth and differentiation in human cementoblasts and to determine the underlying mechanism. A series of experiments including MTT, alkaline phosphatase (ALP) activity, alizarin red staining, RT-PCR, and Western blot were carried out to evaluate the proliferation and differentiation of cementoblasts. In addition, the changes of Wnt signaling pathway molecules were checked to analyze the possible mechanism. Compared to the treatment of cementoblasts with either FGF 2 or dexamethasone alone, the combination of FGF-2 and dexamethasone synergistically increased cell proliferation, ALP activity, nodule formation, and expression of differentiation markers. In addition, FGF 2 and dexamethasone enhanced expression of Wnt3a, Runx2, β-catenin, and p-GSK-3β, all of which were inhibited by DKK1. Taken together, FGF-2 and dexamethasone act synergistically, enhancing each other's ability to stimulate cementoblast growth and differentiation via Wnt signaling pathways. These results support the therapeutic potential of a combination strategy for facilitating cementogenesis and aiding periodontal regeneration.
Indexed as
Identifiers
31938238PMC6958172W3027450002What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.